Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064185 | 0.82 | HSP90AB1 (0.50) | ALDH1A1RAB9ANPC1HSP90AB1CYP4F2 | |
| SCHEMBL1525168 | 0.81 | SMN1; SMN2 (0.47) | ALDH1A1RAB9ANPC1JAK2JAK1 | |
| SCHEMBL21679094 | 0.81 | CYP11B1 (0.46) | ALDH1A1RAB9ANPC1LMNAMAPT | |
| SCHEMBL23169558 | 0.80 | STK17B (0.40) | ALDH1A1RAB9ANPC1LMNAMAPT | |
| SCHEMBL29515142 | 0.80 | ALDH1A1 (0.76) | ALDH1A1RAB9ANPC1HSP90AB1CYP4F2 | |
| SCHEMBL1976605 | 0.80 | ALDH1A1 (0.76) | ALDH1A1RAB9ANPC1HSP90AB1CYP4F2 | |
| SCHEMBL25406145 | 0.79 | HSP90AB1 (0.47) | ALDH1A1RAB9ANPC1HSP90AB1CYP4F2 | |
| SCHEMBL3710578 | 0.79 | ALDH1A1 (0.50) | ALDH1A1RAB9ANPC1HSP90AB1CYP4F2 | |
| SCHEMBL2724216 | 0.78 | ALDH1A1 (0.41) | ALDH1A1RAB9ANPC1 | |
| SCHEMBL22148302 | 0.78 | NPC1 (0.49) | ALDH1A1RAB9ANPC1HSP90AB1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | CYTOSINLAB THERAPEUTICS CO LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| CN-118307534-A | LTA4H inhibitors and uses thereof | 上海海雁医药科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2024012461-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | 上海赛岚生物科技有限公司 | 2024-01-18 | — | — | WO | disclosed |
| CN-117384153-A | Methyltransferase inhibitors and uses thereof | 上海赛岚生物科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| CN-112513017-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 爱尔兰詹森科学公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | ALDH1A1 1223/4885RAB9A 3449/4885NPC1 1218/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | ALDH1A1 1247/4885RAB9A 3316/4885NPC1 830/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | ALDH1A1 1223/4885RAB9A 3449/4885NPC1 1218/4885 |
| US-20260015352-A1 | METHYLTRANSFERASE INHIBITOR AND USE THEREOF | EZH2, DOT1L, EHMT1 | ALDH1A1 691/4885RAB9A 2755/4885NPC1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.